Clinical efficacy of CyberKnife combined with chemotherapy and hyperthermia for advanced non-small cell lung cancer
Authors:
- 19 March 2013
- journal article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 1 (3) , 527-530
Abstract
Non‑small cell lung cancer (NSCLC) is responsible for at least 80% of all lung tumors and has a poor prognosis, since 75% of NSCLCs are first diagnosed at an advanced stage. This study was conducted to evaluate the therapeutic efficacy of CyberKnife in combination with chemotherapy and hyperthermia for selected patients with advanced non‑small cell lung cancer (NSCLC). Clinical charts, imaging and pathology reports of patients with advanced NSCLC who underwent CyberKnife therapy in our Tumor Therapy Center were retrospectively reviewed. Clinical efficacy was evaluated for local control, Karnofsky performance status scale (KPS) and toxicity analysis. A total of 119 patients with 136 target areas were evaluated. A prescribed dose of 24-51 Gy to the gross tumor volume was delivered in 3-6 fractions. The median prescription dose was 35 Gy (mean, 34.73±4.80 Gy), with an average of five fractions. Patients, who voluntarily participated in the study, were assigned to one of three groups, which were as follows: CyberKnife therapy alone, CyberKnife combined with chemotherapy and CyberKnife combined with chemotherapy and hyperthermia. The median follow‑up period was 6 months and curative efficiencies were 62.16, 71.79 and 90.70%, respectively, as determined by radiographic and clinical re‑examinations. Patients treated by CyberKnife combined with chemotherapy and hyperthermia achieved optimal improvement in the aspect of KPS, which was statistically different compared to the other two groups (P<0.05). In conclusion, our results indicated that CyberKnife combined with chemotherapy and hyperthermia achieved favorable short‑term outcomes and may be a more viable option for patients with advanced NSCLC. However, further investigations are required to evaluate long‑term outcomes.Keywords
This publication has 17 references indexed in Scilit:
- Lymphoma cells with increased anti-oxidant defenses acquire chemoresistanceExperimental and Therapeutic Medicine, 2012
- Radiotherapy and chemotherapy for elderly patients with stage I–II unresected lung cancerEuropean Respiratory Journal, 2012
- Concurrent high-dose radiotherapy with low-dose chemotherapy in patients with non-small cell lung cancer of the superior sulcusRadiotherapy and Oncology, 2011
- Phase I Study of Concurrent High-Dose Three-Dimensional Conformal Radiotherapy With Chemotherapy Using Cisplatin and Vinorelbine for Unresectable Stage III Non-Small-Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: Preliminary resultsInternational Journal of Hyperthermia, 2009
- Lung Metastases Treated by CyberKnife® Image-Guided Robotic Stereotactic Radiosurgery at 41 MonthsSouthern Medical Journal, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors.Computer Aided Surgery, 2007
- Prediction of anti-tumour effect of thermochemotherapy within vitrothermochemosensitivity testing for non-small cell lung cancerInternational Journal of Hyperthermia, 2007
- Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell linesCancer Chemotherapy and Pharmacology, 2000